prostate small cell carcinoma

Pathology

• androgen-insensitive carcinoma

Clinical manifestations

• visceral metastases
• lytic bone metastases
• bulky lymph node tumor mass
• bulky prostate tumor mass

Laboratory

• serum prostate-specific antigen (PSA) < 10 ng/mL

Management

• platinum-based chemotherapy
• carboplatin plus docetaxel (75 mg/m2) every 3 weeks
• salvage therapy upon disease progression
  • etoposide (120 mg/m2) plus cisplatin (25 mg/m2) daily for 3 days every 3 weeks

More general terms

• small cell carcinoma